Moderna Inc. (NASDAQ: MRNA) announced that Phase 3 clinical trial results for its investigational seasonal influenza vaccine mRNA-1010 have been ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE